Baxter International Inc. (NYSE: BAX) announces the $112 million divestiture of their generic injectables business to Hikma Pharmaceuticals PLC.

This article: 311 words
-->

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE